Great question! Sarclisa (isatuximab-irfc) doesn't have to be paired with lenalidomide. There are combination options available, particularly for those whose myeloma has relapsed or is no longer responding to lenalidomide-based treatment.
One well-studied combination is Sarclisa with pomalidomide and dexamethasone. This Show Full Answer
Great question! Sarclisa (isatuximab-irfc) doesn't have to be paired with lenalidomide. There are combination options available, particularly for those whose myeloma has relapsed or is no longer responding to lenalidomide-based treatment.
One well-studied combination is Sarclisa with pomalidomide and dexamethasone. This regimen has been used in clinical trials and is a recognized option for relapsed or refractory myeloma. Pomalidomide (Pomalyst) is an immunomodulatory drug similar to lenalidomide but designed for use when earlier treatments, including lenalidomide, have stopped working. It's typically considered after at least two prior lines of therapy.
Here's a quick summary of what this path might look like:
- Sarclisa + pomalidomide + dexamethasone — a combination used in relapsed/refractory myeloma
- Pomalidomide steps in when lenalidomide is no longer effective
- Dexamethasone is a steroid commonly added to boost the effectiveness of the regimen
The best combination will always depend on treatment history, how the myeloma is behaving, and overall health. A conversation with a myeloma specialist is the best way to explore which option fits best.
August 13
Join
Your Privacy Choices
